Session Abstract – PMWC 2022 Silicon Valley

 Session Chair Profile

Ph.D., Senior Vice President of Strategic Research & Scientific Co-Founder, immunai

Biography
Danny Wells is a scientific co-founder at Immunai and currently serves as the Senior Vice President of Strategic Research. Danny joined the founding team of Immunai during his time as an investigator at the Parker Institute for Cancer Immunotherapy, where he was the founding principal data scientist and led research efforts in genomics and reverse translational medicine. Danny has co-authored dozens of research articles around the intersection of (single-cell) genomics and cancer immunotherapy that have collectively been cited thousands of times, including papers published in Nature, Cell, and Nature Medicine. Before joining the Parker Institute, Danny completed a postdoctoral fellowship in evolutionary biology at the University of California, Berkeley, his PhD in Computational Biology and Applied Mathematics at Northwestern University, where he was an NSF Graduate Research Fellow, and a BA in Mathematics from Carleton College where received the Galovich Prize for accomplishment in undergraduate mathematics research.


 Speaker Profile

Ph.D., Principal Scientist/ Senior Director, Genentech

Biography
Sanjeev Mariathasan leads the biomarker strategy for the Atezolizumab/Tecentriq franchise. He also co-leads the Oncology Reverse Translation group. The aim of this group is to derive mechanistic and therapeutically actionable insights from Roche’s extensive clinical database as well as to identify novel targets for the cancer immunotherapy pipeline. Examples of his research include (1) the revelation of TGFβ-mediated signaling in aiding exclusion of T cells in stromal tissues surrounding the tumors and the demonstration of reversing these effects leading to enhanced anti-tumor efficacy with anti-TGFβ and anti-PD-L1 mAb combination therapy in preclinical models (Mariathasan et al, Nature 2018); and (2) the use of ctDNA as an exploratory endpoint in a phase 3 adjuvant bladder cancer trial, the results of which have the potential to change treatment decision paradigms in early-stage bladder cancer and potentially other solid tumor types (Powles et al, Nature 2021).

Talk
Peripheral Biomarkers Guiding Cancer Immunotherapy